Department of Internal Medicine, Lankenau Medical Center , Wynnewood, PA, 19096, USA.
Division of Cardiovascular Disease, Lankenau Heart Institute . 19096, Wynnewood, PA, USA.
Expert Opin Drug Deliv. 2020 Oct;17(10):1335-1343. doi: 10.1080/17425247.2020.1789586. Epub 2020 Jul 3.
The Zilver PTX stent was the first self-expanding drug-coated stent approved by the United States Food and Drug Administration (US FDA) for use in the superficial femoral artery (SFA) above the knee. The main objective of this article is to review the design, safety, and efficacy of the Zilver PTX stent which was engineered to outperform bare metal stents (BMS) in this challenging environment.
An evaluation of the Zilver PTX peripheral paclitaxel-coated stent design and a review of the current preclinical and clinical evidence regarding the use of this stent.
Stent implantation for the treatment of peripheral arterial disease (PAD) in the SFA was initially seen as a salvage option; however, stenting is now routinely offered as initial therapy for patients suffering from claudication and critical limb ischemia. The Zilver PTX stent has established efficacy and safety profiles for paclitaxel in the SFA; however, the development of biocompatible polymers capable of extending the elution time of anti-proliferative agents may lead to more effective stent platforms.
Zilver PTX 支架是首个获得美国食品和药物管理局（FDA）批准用于膝上股浅动脉（SFA）的自膨式药物涂层支架。本文的主要目的是回顾 Zilver PTX 支架的设计、安全性和疗效，该支架旨在超越裸金属支架（BMS）在这一具有挑战性的环境中的表现。
评估 Zilver PTX 外周紫杉醇涂层支架的设计，并回顾当前关于使用这种支架的临床前和临床证据。
最初，支架植入术被视为外周动脉疾病（PAD）治疗 SFA 的一种挽救性选择；然而，支架现在已常规用于治疗有跛行和严重肢体缺血的患者。Zilver PTX 支架在 SFA 中已确立了紫杉醇的疗效和安全性；然而，开发具有生物相容性的聚合物，能够延长抗增殖药物的洗脱时间，可能会导致更有效的支架平台。
